Limited experience with doses higher than the approved intravenous doses of Rituximab is available from clinical trials in humans. The highest IV dose tested in humans to date is 5000 mg (2,250 mg/m2), tested in a dose escalation study in patients with chronic lymphocytic leukemia. No additional safety signals were identified. Patients who experience overdose should have immediate interruption of their infusion and be closely monitored.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
